Payment overview · 2025
General Payments
$2,047.63
112 reported records · 29 companies
Healthcare provider profile · identity verified
James P Wallace, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DILLON, SC · NPI 1487741146
Verified facts
What the public records show
CMS Open Payments records show James P Wallace, MD received $2,047.63 in general payments during 2025 across 112 reported records.
PFIZER INC. accounted for 10.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 499 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 499 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 413 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $218.15 | 10.7% | 13 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $205.32 | 10.0% | 10 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $169.34 | 8.3% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $128.44 | 6.3% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $112.39 | 5.5% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $112.30 | 5.5% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $108.85 | 5.3% | 6 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $97.76 | 4.8% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $96.81 | 4.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $92.53 | 4.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $80.83 | 4.0% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $70.27 | 3.4% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $67.89 | 3.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.79 | 2.7% | 3 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $48.74 | 2.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.17 | 1.9% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $37.16 | 1.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $36.49 | 1.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $35.42 | 1.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.64 | 1.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.99 | 1.5% | 2 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $28.75 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.25 | 1.4% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $25.81 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.81 | 1.1% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $19.68 | 1.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.00 | 0.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.57 | 0.8% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $13.48 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,047.63 | 112 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $205.32 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $194.90 | 12 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $169.34 | 11 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $169.34 | 11 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $169.34 | 11 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $112.39 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $112.30 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $108.85 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $106.97 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $106.97 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $105.29 | 6 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $97.76 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $96.81 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $89.61 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $76.30 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $67.89 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $55.30 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.91 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.91 | 3 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $48.74 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $48.74 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $44.84 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $44.28 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $38.17 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $37.16 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $36.49 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $35.42 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.64 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $29.92 | 2 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $28.75 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.25 | 3 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 413 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 229 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 499 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 38 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 105 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 129 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 213 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
105 | 40 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
31 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
499 | 112 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
213 | 59 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
105 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
499 | 112 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
129 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
218 | 51 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
229 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
413 | 91 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1370 | 338 |
| Amlodipine Besylate | Amlodipine Besylate | 1076 | 332 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1076 | 376 |
| Gabapentin | Gabapentin | 907 | 201 |
| Metoprolol Succinate | Metoprolol Succinate | 773 | 230 |
| Omeprazole | Omeprazole | 752 | 189 |
| Losartan Potassium | Losartan Potassium | 696 | 240 |
| Pravastatin Sodium | Pravastatin Sodium | 694 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 662 | 160 |
| Pantoprazole Sodium | Pantoprazole Sodium | 554 | 143 |
| Furosemide | Furosemide | 521 | 126 |
| Jardiance | Empagliflozin | 499 | 112 |
| Carvedilol | Carvedilol | 444 | 111 |
| Eliquis | Apixaban | 413 | 91 |
| Potassium Chloride | Potassium Chloride | 393 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 386 | 102 |
| Doxazosin Mesylate | Doxazosin Mesylate | 380 | 101 |
| Hydrochlorothiazide | Hydrochlorothiazide | 352 | 126 |
| Allopurinol | Allopurinol | 346 | 69 |
| Metformin Hcl | Metformin Hcl | 329 | 95 |
| Prednisone | Prednisone | 325 | 139 |
| Benazepril Hcl | Benazepril Hcl | 308 | 108 |
| Tramadol Hcl | Tramadol Hcl | 305 | 137 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 303 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 298 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 292 | 64 |
| Montelukast Sodium | Montelukast Sodium | 273 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 252 | 109 |
| Ezetimibe | Ezetimibe | 251 | 88 |
| Valsartan | Valsartan | 249 | 28 |
| Entresto | Sacubitril/Valsartan | 229 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 229 | 112 |
| Spironolactone | Spironolactone | 224 | 50 |
| Hydralazine Hcl | Hydralazine Hcl | 220 | 62 |
| Trulicity | Dulaglutide | 218 | 51 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 213 | 59 |
| Metformin Hcl Er | Metformin Hcl | 211 | 77 |
| Lisinopril | Lisinopril | 195 | 72 |
| Clonazepam | Clonazepam | 186 | 45 |
| Amoxicillin | Amoxicillin | 184 | 143 |
| Zolpidem Tartrate | Zolpidem Tartrate | 183 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 182 | 46 |
| Meloxicam | Meloxicam | 177 | 63 |
| Alendronate Sodium | Alendronate Sodium | 167 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 152 | 30 |
| Sertraline Hcl | Sertraline Hcl | 151 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 147 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 145 | 30 |
| Memantine Hcl | Memantine Hcl | 144 | 13 |
| Levetiracetam | Levetiracetam | 141 | 16 |
| Buspirone Hcl | Buspirone Hcl | 140 | 14 |
| Famotidine | Famotidine | 140 | 33 |
| Trazodone Hcl | Trazodone Hcl | 137 | 32 |
| Glimepiride | Glimepiride | 136 | 46 |
| Warfarin Sodium | Warfarin Sodium | 134 | 18 |
| Mounjaro | Tirzepatide | 129 | 32 |
| Cefdinir | Cefdinir | 128 | 110 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 128 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 117 | 14 |
| Mirtazapine | Mirtazapine | 114 | suppressed |
| Ramipril | Ramipril | 111 | 37 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 109 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 35 |
| Linzess | Linaclotide | 105 | 40 |
| Pregabalin | Pregabalin | 102 | 39 |
| Sucralfate | Sucralfate | 101 | 30 |
| Xarelto | Rivaroxaban | 98 | 16 |
| Bumetanide | Bumetanide | 96 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 96 | 22 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 90 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 89 | 33 |
| Bupropion Xl | Bupropion Hcl | 88 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 38 |
| Simvastatin | Simvastatin | 85 | 37 |
| Meclizine Hcl | Meclizine Hcl | 84 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 22 |
| Chlorthalidone | Chlorthalidone | 81 | 29 |
| Finasteride | Finasteride | 81 | 27 |
| Midodrine Hcl | Midodrine Hcl | 80 | 13 |
| Nifedipine Er | Nifedipine | 78 | 27 |
| Olanzapine | Olanzapine | 78 | suppressed |
| Risperidone | Risperidone | 78 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 73 | 37 |
| Atenolol | Atenolol | 72 | 19 |
| Colchicine | Colchicine | 71 | 23 |
| Fluconazole | Fluconazole | 71 | 47 |
| Donepezil Hcl | Donepezil Hcl | 70 | 11 |
| Mupirocin | Mupirocin | 69 | 49 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 68 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 60 |
| Ibuprofen | Ibuprofen | 66 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 43 |
| Indapamide | Indapamide | 64 | 24 |
| Synthroid | Levothyroxine Sodium | 64 | 16 |
| Azithromycin | Azithromycin | 62 | 52 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 25 |
| Labetalol Hcl | Labetalol Hcl | 59 | 13 |
| Lansoprazole | Lansoprazole | 59 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 18 |
| Glipizide | Glipizide | 55 | suppressed |
| Nystatin | Nystatin | 55 | 34 |
| Benztropine Mesylate | Benztropine Mesylate | 52 | suppressed |
| Celecoxib | Celecoxib | 52 | 19 |
| Leflunomide | Leflunomide | 52 | suppressed |
| Haloperidol | Haloperidol | 51 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 51 | suppressed |
| Sotalol | Sotalol Hcl | 51 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 50 | 46 |
| Ranolazine Er | Ranolazine | 50 | suppressed |
| Lactulose | Lactulose | 49 | 18 |
| Levofloxacin | Levofloxacin | 49 | 41 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 14 |
| Alprazolam | Alprazolam | 47 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 15 |
| Januvia | Sitagliptin Phosphate | 47 | 19 |
| Lorazepam | Lorazepam | 47 | 12 |
| Nitroglycerin | Nitroglycerin | 47 | 22 |
| Myrbetriq | Mirabegron | 45 | 14 |
| Tradjenta | Linagliptin | 45 | 15 |
| Farxiga | Dapagliflozin Propanediol | 44 | 16 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 27 |
| Rivastigmine | Rivastigmine Tartrate | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 16 |
| Calcitriol | Calcitriol | 41 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 39 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Cilostazol | Cilostazol | 39 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 39 | 22 |
| Clonidine Hcl | Clonidine Hcl | 38 | 15 |
| Kerendia | Finerenone | 38 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | 12 |
| Repatha Sureclick | Evolocumab | 37 | 13 |
| Ozempic | Semaglutide | 35 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | 11 |
| Gemfibrozil | Gemfibrozil | 32 | 11 |
| Levemir Flexpen | Insulin Detemir | 32 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 12 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 31 | 31 |
| Prolia | Denosumab | 31 | 21 |
| Propranolol Hcl | Propranolol Hcl | 31 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 30 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 27 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | 12 |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 17 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 19 |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Metolazone | Metolazone | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Amantadine | Amantadine Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Dofetilide | Dofetilide | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 16 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 18 | 18 |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Budesonide | Budesonide | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 17 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 13 |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Apidra | Insulin Glulisine | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Crestor | Rosuvastatin Calcium | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,047.63 · 112 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FREESTYLE LIBRE 3, Fluad, Flucelvax, GEMTESA, INJECTAFER, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, LORBRENA, MOUNJARO, NALOCET, NEXLETOL, NURTEC ODT, OTEZLA, PREVNAR 20, PROLATE, QULIPTA, REPATHA, SHINGRIX, Symbravo, TANLOR, TRELEGY ELLIPTA, Trodelvy, UBRELVY, VERQUVO, VIBERZI, VOQUEZNA, VRAYLAR, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, ZTLido | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error